Last reviewed · How we verify
BIAsp30
BIAsp30 is a biphasic insulin aspart formulation that provides both rapid-acting and intermediate-acting insulin coverage to control blood glucose levels.
BIAsp30 is a biphasic insulin aspart formulation that provides both rapid-acting and intermediate-acting insulin coverage to control blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | BIAsp30 |
|---|---|
| Sponsor | The First Hospital of Jilin University |
| Drug class | Premixed insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
BIAsp30 is a premixed insulin containing 30% insulin aspart (rapid-acting) and 70% insulin aspart protamine suspension (intermediate-acting). The rapid component begins working within 10-20 minutes to address postprandial glucose spikes, while the intermediate component provides basal insulin coverage over 24 hours. This combination allows for simplified once or twice-daily dosing in patients requiring both prandial and basal insulin.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
- Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs (PHASE4)
- Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects (PHASE1)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
- Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids (PHASE4)
- A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria
- A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects (NA)
- Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIAsp30 CI brief — competitive landscape report
- BIAsp30 updates RSS · CI watch RSS
- The First Hospital of Jilin University portfolio CI